Vaccinex, Inc.
VCNX · OTC · United States
Share price · VCNX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VCNX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Aug 2026+60.3%
Nothing announced by VCNX that day or the session before.
- 3 Aug 2026+35.3%
Nothing announced by VCNX that day or the session before.
- 31 Jul 2026-28.0%
Nothing announced by VCNX that day or the session before.
- 21 Jul 2026+35.6%
Nothing announced by VCNX that day or the session before.
- 20 Jul 2026-24.3%
Nothing announced by VCNX that day or the session before.
- 29 Jun 2026+29.9%
Nothing announced by VCNX that day or the session before.
- 23 Jun 2026-24.5%
Nothing announced by VCNX that day or the session before.
- 4 Jun 2026+29.9%
Nothing announced by VCNX that day or the session before.
- 16 Mar 2026+42.9%
Nothing announced by VCNX that day or the session before.
- 6 Mar 2026+31.1%
Nothing announced by VCNX that day or the session before.
Share of unusual movement by asset
For each asset, the share of VCNX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Pepinemabevents and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 4% |
| Sessions with no dated event | — | 95% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | SEMA4DMonoclonal antibody | Alzheimer's DiseaseHead and Neck Squamous Cell Carcinoma Early Alzheimer's Disease |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (10)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q3 | $0.1M | $3.2M | $2.9M | $5.7M-$3.2M operating cash flow | report ↗ |
Vaccinex reported revenue of $0.05M, up 150.0% YoY, with R&D spend of $3.17M, down 27.3% YoY. Cash and equivalents stood at $2.91M, and the company posted a net loss of $5.73M, equivalent to a quarterly net burn of $5.73M.
The filing discloses substantial doubt about the company’s ability to continue as a going concern, citing cash used in operations of $12.3M for the nine months ended September 30, 2024 and an accumulated deficit of $355.2M. No financial guidance or clinical pipeline updates were reported.
View 9 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | $0.2M | $3.9M | $0.2M | $5.6M-$4.4M operating cash flow | report ↗ |
| 2024-Q1 | $0.1M | $3.4M | $3.0M | $3.9M-$4.6M operating cash flow | report ↗ |
| 2023-Q3 | <$0.1M | $4.4M | $0.1M | $4.9M-$3.1M operating cash flow | report ↗ |
| 2023-Q2 | — | $5.0M | $1.9M | $7.1M-$5.5M operating cash flow | report ↗ |
| 2023-Q1 | $0.6M | $3.8M | $3.3M | $5.0M-$5.0M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $3.4M | $7.2M | $4.8M-$4.2M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.8M | $11M | $5.4M-$5.3M operating cash flow | report ↗ |
| 2022-Q1 | — | $3.0M | $17M | $4.6M-$5.0M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $3.6M | $14M | $5.2M-$6.1M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0.6M | $13M | $1.1M | $4.7M-$16M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2024-11-14 | Zauderer Maurice; Vaccinex (Rochester), L.L.C. · director, President and CEO, 10% owner; 10% owner | Award / grant | 46,153 | $3.25 | $150K | Form 4 |
| 2024-11-14 | FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% owner | Award / grant | 30,756 | $3.25 | $100K | Form 4 |
| 2024-11-14 | FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% owner | Award / grant (derivative) | 584,646 | $3.25 | $1.9M | Form 4 |
| 2024-09-18 | FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% owner | Option exercise | 214,286 | $5.64 | $1.2M | Form 4 |
| 2024-09-18 | Zauderer Maurice; Vaccinex (Rochester), L.L.C. · director, President and CEO, 10% owner; 10% owner | Option exercise | 38,610 | $5.64 | $218K | Form 4 |
| 2024-09-18 | FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% owner | Option exercise | 25,723 | $5.64 | $145K | Form 4 |
| 2024-09-18 | Zauderer Maurice; Vaccinex (Rochester), L.L.C. · director, President and CEO, 10% owner; 10% owner | Option exercise | 29,557 | $5.64 | $167K | Form 4 |
| 2024-09-18 | FRIEDBERG ALBERT; FCMI Parent Co. · director, 10% owner; 10% owner | Option exercise (derivative) | 214,286 | — | — | Form 4 |